全球制药巨头诺华和礼来近日宣布与Alphabet（谷歌母公司）旗下的AI制药企业Isomorphic Labs达成战略合作，总价值高达30亿美元。这一合作将利用AI技术开发新药，重点关注小分子多靶点药物。
Isomorphic Labs是一家专注于AI药物发现的初创公司，其技术有望加速新药的研发流程，并降低研发成本。此次合作将使诺华和礼来能够利用Isomorphic Labs的AI技术，发现和开发新的药物候选物。
根据协议，诺华和礼来将向Isomorphic Labs支付总计30亿美元的款项，用于获取使用其AI技术的权利。此外，如果未来开发的药物销售顺利，Isomorphic Labs还有望获得特许权使用费。
此次合作是AI制药领域的一大突破，也展示了全球制药巨头对AI技术在药物研发中潜力的认可。AI技术的应用有望改变传统药物研发的模式，加快新药的上市速度，并为患者带来更多的治疗选择。
英文标题：Novartis, Lilly in $3B Pact With Google Parent’s AI Drug Firm
Keywords: Novartis, Lilly, AI Pharmaceuticals
News content:
Global pharmaceutical giants Novartis and Lilly have recently announced a strategic collaboration with Isomorphic Labs, an AI pharmaceutical startup owned by Alphabet (the parent company of Google), with a total value of up to $3 billion. This partnership will utilize AI technology to develop new drugs, with a focus on small molecule multi-target drugs.
Isomorphic Labs is a startup focused on AI drug discovery, whose technology is expected to accelerate the research and development process of new drugs and reduce costs. This collaboration will allow Novartis and Lilly to use Isomorphic Labs’ AI technology to discover and develop new drug candidates.
According to the agreement, Novartis and Lilly will pay a total of $3 billion to Isomorphic Labs for the right to use its AI technology. In addition, if the drugs developed in the future achieve successful sales, Isomorphic Labs may also receive royalties.
This collaboration is a significant breakthrough in the field of AI pharmaceuticals and demonstrates the recognition of the potential of AI technology in drug research and development by global pharmaceutical giants. The application of AI technology is expected to change the traditional model of drug research and development, accelerate the launch of new drugs, and bring more treatment options to patients.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 7